Advertisement
U.S. markets open in 5 hours 13 minutes

23andMe Holding Co. (ME)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.5104+0.0226 (+4.63%)
At close: 04:00PM EDT
0.5169 +0.01 (+1.27%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close0.4878
Open0.4905
Bid0.5094 x 200
Ask0.5162 x 200
Day's Range0.4622 - 0.5249
52 Week Range0.4010 - 2.3200
Volume4,760,016
Avg. Volume7,150,586
Market Cap246.481M
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ME

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • 23andMe Holding Co.
    Analyst Report: 23andMe Holding Co.23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
    Rating
    Fair Value
    Economic Moat
    2 years agoMorningstar
View more